Biogen Idec Articles
Stock Commentary - Europe
22 November 2004
Elan completes $1.5B senior notes offering
22 November 2004
Stock Commentary - Europe
15 November 2004
Biogen Idec and Dyax in antibody alliance
15 November 2004
Biogen's 3rd-qtr profit falls on merger costs
8 November 2004
Biogen Idec opens new San Diego campus
8 November 2004
UPDATE: Serono tops forecasts as EPS rockets 54%
1 November 2004
Elan denies merger talks with Biogen Idec
25 October 2004
Biogen Idec eyeing up Elan acquisition?
25 October 2004
ImmunoGen and Biogen Idec in oncology deal
11 October 2004
Elan/Biogen Idec's Antegren filed for Crohn's disease in EU
4 October 2004
Vernalis cuts first-half 2004 loss 50%
27 September 2004
Biogen and Sunesis enter collaboration
20 September 2004
Biogen Idec/Elan's Antegren update
23 August 2004
Strong 1st-half results for Richter Gedeon
9 August 2004
Biogen Idec enters Swiss lion's den
9 August 2004
Stock Commentary - New York
9 August 2004
Promotions at Biogen Idec
9 August 2004
Biogen Idec closes 2nd-qtr above expectations
9 August 2004
Elan posts $117.6M 2nd-qtr net loss
9 August 2004
Sunesis in antiviral deal with Merck & Co
2 August 2004
Elan/Biogen's NDA for Antegren accepted
2 August 2004
Biogen Idec selects Evotec as service provider
26 July 2004
Vernalis leaps 104% on $400M Frova deal
26 July 2004
Stock Commentary - Europe
12 July 2004
New international HQ for Biogen Idec
12 July 2004
Stock Commentary - Europe
5 July 2004
Stock Commentary - New York
5 July 2004
Priority review for Biogen/Elan's Antegren
5 July 2004
Biogen Idec's Amevive OKed in Australia
28 June 2004
EU filing for Biogen/Elan's Antegren
14 June 2004
Stock Commentary - New York
7 June 2004
Stock Commentary - New York
31 May 2004
Biogen/Elan's Antegren filed for MS in USA
31 May 2004
Biogen Idec's Amevive cleared in Israel
10 May 2004
Promising Ph II data for Biogen's BG-12
10 May 2004
Biogen Idec's 1st-qtr revenues rise 24%
10 May 2004
Elan/Biogen Idec to file Antegren in EU
29 March 2004
SurroMed expands accord with Biogen Idec
15 March 2004
Merger costs Biogen Idec a $991M loss
8 March 2004
Stock Commentary - Europe
1 March 2004
Stock Commentary - New York
1 March 2004
Elan/Biogen Idec's Antegren to be filed for MS early
23 February 2004
Stock Commentary - Europe
23 February 2004
Celltech and Biogen Idec sign deal
16 February 2004
Antegren to be studied in RA patients
9 February 2004
Elan/Biogen Idec's Antegren meets goal
9 February 2004
Schering AG's Zevalin cleared by EC
26 January 2004
MabThera EU filing for first-line indolent NHL
26 January 2004
New Chemical Entities in 2003
19 January 2004
Nippon Shinyaku and Biogen Idec end HMN-214 deal
5 January 2004
US Medicare bill and biotech reimbursement
15 December 2003
Biogen and IDEC to merge in $6.78Bn deal
30 June 2003
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
